2015
Romidepsin for the Treatment of Peripheral T‐Cell Lymphoma
Iyer SP, Foss FF. Romidepsin for the Treatment of Peripheral T‐Cell Lymphoma. The Oncologist 2015, 20: 1084-1091. PMID: 26099743, PMCID: PMC4571813, DOI: 10.1634/theoncologist.2015-0043.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaT-cell lymphomaHistone deacetylase inhibitorsPrior therapySpecialty centersTherapeutic approachesExpert hematopathologistsTreatment of PTCLDeacetylase inhibitorsPivotal phase II studiesCutaneous T-cell lymphomaPrior systemic therapyCommon adverse eventsObjective response ratePhase II studyFirst-line treatmentTreatment of patientsNon-Hodgkin lymphomaDifficulty of diagnosisAsthenic conditionsHeavy pretreatmentInduction chemotherapyAdvanced diseaseAdverse events
2011
Peripheral T-cell lymphoma
Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood 2011, 117: 6756-6767. PMID: 21493798, DOI: 10.1182/blood-2010-05-231548.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaStandard chemotherapeutic regimensBest treatment strategyMore effective therapiesHistone deacetylase inhibitorsWorld Health OrganizationAbundance of drugsAggressive diseaseChemotherapeutic regimensPoor outcomeTreatment optionsClinical trialsEffective therapyTreatment strategiesTherapeutic approachesPrognostic issuesDeacetylase inhibitorsLymphoma classificationMonoclonal antibodiesGene expression profilingHeterogeneous groupHealth OrganizationProteasome inhibitorsDisease biology
2003
Overview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic Approaches
Foss F. Overview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic Approaches. Leukemia & Lymphoma 2003, 44: s55-s61. PMID: 15202526, DOI: 10.1080/10428190310001623757.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaNovel agentsTherapeutic approachesAcute T-cell leukemia/lymphomaAdvanced refractory cutaneous T cell lymphomasEarly-stage cutaneous T-cell lymphomaMycosis fungoides/Sézary syndromeRefractory cutaneous T-cell lymphomaPeripheral T-cell lymphomaAllogeneic stem cell therapyT-cell leukemia/lymphomaDemonstrated survival benefitYear of diagnosisAdvanced-stage patientsCytokine receptor antagonistsProbability of progressionNovel therapeutic approachesLeukemia/lymphomaNew therapeutic approachesNF-kappaB inhibitorHistone deacetylase inhibitorsStem cell therapyCytotoxic regimensExtracutaneous disease